ALT Stock — Altimmune, Inc.

Altimmune, Inc. (ALT)

Updated October 16, 2026.

ALT is a Stock. Its deepest 1-year drawdown was 64.4%.

Altimmune, Inc. is a late-stage biopharmaceutical company developing novel therapies for serious liver diseases, with its lead candidate pemvidutide, a GLP-1/glucagon dual receptor agonist, currently in Phase 3 clinical trials for metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company does not currently distribute to shareholders. This security appeals to investors seeking exposure to clinical-stage biotech companies with potentially transformative drug candidates rather than those focused on current income.

ALT performance

Returns are updating. ALT's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 64.4%.

ALT key facts

Asset type

Stock

Asset class

Equity

Inception date

10/06/2005

Distribution frequency

None

Last close

$2.20 (as of 2026-10-16)

Market cap

$427,938,942

Average volume

4233935.0

Ex-dividend date

01/20/2017

Beta

0.059

Payout ratio

0.0%

Forward P/E

8.1766

EPS

$-0.76

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ALT risks and drawbacks

The deepest 1-year drawdown on record here is 64.4%.

Who may consider ALT — and who may not

It is a weaker fit for investors who need monthly cash flow (ALT does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on ALT

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions